Respiratory disorders include conditions such as asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and community acquired pneumonia (CAP), while metabolic disorders include diabetes, dyslipidemia, obesity and metabolic syndrome, which is defined as a cluster of conditions that damage the cardiovascular system... MDS Pharma Services' Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
June
(39)
- M. D. Anderson and Aureon Laboratories : to Evalua...
- Aradigm : Phase 2 Study of Inhaled Liposomal Cipro...
- Alnylam and Kyowa Hakko : Alliance for the Develop...
- Altus Pharmaceuticals : Last Patient Visit Of Triz...
- Transave : POSITIVE PHASE II RESULTS FOR ONCE-DAIL...
- Gilead : Interim 12-Month Phase III Study Results ...
- Pharmacopeia and GlaxoSmithKline Collaboration : a...
- Banner Pharmacaps : FDA Approval for Amantadine S...
- ImmunoCellular Therapeutics : Research Agreement w...
- Vitrolife : STEEN Solution approved for sales in A...
- Pharmaxis : Special Protocol Assessment with FDA f...
- FASgen : Production and Investment Agreement with ...
- Vall d’Hebron University Hospital and Cyclacel Pha...
- Ikaria : INOFLO (NITRIC OXIDE) FOR INHALATION TO B...
- Boehringer Ingelheim : to acquire Actimis Pharmace...
- SkyePharma : Second Flutiform Phase III Efficacy S...
- ALK-Abelló : GRAZAX® Demonstrates Significant Redu...
- Anesiva and Transcription Factor Therapeutics : Li...
- AstraZeneca submits an sNDA for SYMBICORT® for the...
- Critical Therapeutics : Phase II Clinical Trial fo...
- Novavax : Proprietary Method to Create SARS Vaccin...
- Jennerex Promising Results from Cancer Clinical T...
- Emphasys Medical : VENT Clinical Trial Data at ATS...
- Angiotech : completion of Bio-Seal clinical trial ...
- Bayer HealthCare and Nektar Therapeutics : Amikaci...
- Lilly : Study Showed ALIMTA (pemetrexed for injec...
- GlaxoSmithKline : New data for pazopanib – GSK’s l...
- Rosetta Genomics and M. D. Anderson to Develop a M...
- GlaxoSmithKline : New data on MAGE-A3 cancer immu...
- Pulmo BioTech : Details of the Methodology for its...
- MDS Pharma Services : Therapeutic Focus on Respira...
- DEY : Concomitant Use of Nebulized Formoterol Fuma...
- Almirall & Forest : Positive Results of Clinical S...
- Basilea Pharmaceutica : Ceftobiprole shows high cu...
- Perceptronix Medical : Early Detection Brings Hope
- TeraRecon iNtuition : at the Stanford MDCT face-of...
- Critical Outcome Technologies : Amalgamation With ...
- Dako : unique package of RTU antibodies for cancer...
- Med BioGene and University Health Network : Collab...
-
▼
June
(39)
Jun 10, 2008
MDS Pharma Services : Therapeutic Focus on Respiratory
May 20, 2008 - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has named two experienced medical professionals to lead its late stage clinical trial management activities related to respiratory ailments and metabolic disorders. Dr. Bernard Tisserand and Dr. Jonny L. Salyer have been named Executive Medical Directors for Respiratory Disorders and Metabolic Disorders, respectively. These therapeutic areas represent serious global public health concerns and are key areas of focus for MDS Pharma Services' customers.
Libellés :
Asthma,
Chronic Obstructive Pulmonary Disease (COPD),
MDS